The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
 
Cedric Christophe Nasnas
No Relationships to Disclose
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda
 
Fadi Haddad
No Relationships to Disclose
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Walid Macaron
No Relationships to Disclose
 
Marianne Zoghbi
No Relationships to Disclose
 
Lewis Fady Nasr
No Relationships to Disclose
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); KisoJi Biotechnology (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); Medisix Therapeutics (Inst); MingSight (Inst); Newave Pharmaceutical (Inst); NovalGen (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Sana Biotechnology (Inst); SERVIER (Inst); Takeda (Inst); TransThera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Emmanuel Almanza
No Relationships to Disclose
 
Koji Sasaki
Honoraria - Amgen; Chugai Pharma; Otsuka
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Research Funding - Novartis
Travel, Accommodations, Expenses - Otsuka
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Partow Kebriaei
Honoraria - Kite, a Gilead company; Pfizer
Consulting or Advisory Role - Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Kite, a Gilead company; Pfizer
 
Xuelin Huang
No Relationships to Disclose
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Tapan M. Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; SERVIER
Research Funding - Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst)
 
Sa A Wang
Consulting or Advisory Role - Caprico Biotechnologies, Inc.
Research Funding - Seagen
 
Jovitta Jacob
No Relationships to Disclose
 
Rebecca Garris
No Relationships to Disclose
 
Susan M. O'Brien
No Relationships to Disclose
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)